Michio Imamura

9.6k total citations · 1 hit paper
226 papers, 5.7k citations indexed

About

Michio Imamura is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Michio Imamura has authored 226 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 184 papers in Hepatology, 152 papers in Epidemiology and 29 papers in Infectious Diseases. Recurrent topics in Michio Imamura's work include Hepatitis C virus research (136 papers), Liver Disease Diagnosis and Treatment (109 papers) and Hepatitis B Virus Studies (92 papers). Michio Imamura is often cited by papers focused on Hepatitis C virus research (136 papers), Liver Disease Diagnosis and Treatment (109 papers) and Hepatitis B Virus Studies (92 papers). Michio Imamura collaborates with scholars based in Japan, United States and Switzerland. Michio Imamura's co-authors include Kazuaki Chayama, Masataka Tsuge, Nobuhiko Hiraga, Hiroshi Aikata, Shoichi Takahashi, C. Nelson Hayes, Hidenori Ochi, Hiromi Abe, Yoshiiku Kawakami and Tomokazu Kawaoka and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Nature Communications.

In The Last Decade

Michio Imamura

216 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of the Niemann-Pick C1–like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor

2012 350 citations Nobuhiko Hiraga, Michio Imamura et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michio Imamura Japan	42	3.8k	3.5k	981	659	554	226	5.7k
Theo Heller United States	46	3.3k 0.9×	4.0k 1.1×	1.2k 1.2×	872 1.3×	605 1.1×	235	7.3k
I‐Shyan Sheen Taiwan	47	5.5k 1.5×	5.2k 1.5×	640 0.7×	825 1.3×	322 0.6×	179	7.3k
Ming–Yang Lai Taiwan	41	6.0k 1.6×	5.8k 1.6×	539 0.5×	420 0.6×	599 1.1×	131	7.2k
Jacob Nattermann Germany	36	2.1k 0.6×	1.9k 0.5×	414 0.4×	440 0.7×	494 0.9×	138	4.4k
Keith Meyer United States	36	2.8k 0.7×	2.4k 0.7×	1.1k 1.1×	122 0.2×	444 0.8×	75	4.4k
Shinichi Kakumu Japan	42	3.7k 1.0×	3.6k 1.0×	526 0.5×	328 0.5×	318 0.6×	173	5.5k
Young S. Hahn United States	43	2.0k 0.5×	2.0k 0.6×	1.1k 1.1×	330 0.5×	375 0.7×	92	5.2k
Tatsuya Kanto Japan	46	2.6k 0.7×	2.5k 0.7×	1.9k 1.9×	387 0.6×	301 0.5×	218	6.9k
Chuan–Mo Lee Taiwan	40	4.3k 1.1×	4.3k 1.2×	481 0.5×	780 1.2×	505 0.9×	122	5.9k
Shiu‐Wan Chan United Kingdom	20	2.4k 0.6×	2.2k 0.6×	939 1.0×	114 0.2×	424 0.8×	37	3.9k

Countries citing papers authored by Michio Imamura

Since Specialization

Citations

This map shows the geographic impact of Michio Imamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michio Imamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michio Imamura more than expected).

Fields of papers citing papers by Michio Imamura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michio Imamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michio Imamura. The network helps show where Michio Imamura may publish in the future.

Co-authorship network of co-authors of Michio Imamura

This figure shows the co-authorship network connecting the top 25 collaborators of Michio Imamura. A scholar is included among the top collaborators of Michio Imamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michio Imamura. Michio Imamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Uchida, Takuro, Michio Imamura, C. Nelson Hayes, et al.. (2023). HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice. Hepatology. 78(3). 929–942. 7 indexed citations

Uchida, Takuro, Michio Imamura, Hiromi Abe‐Chayama, et al.. (2022). A novel cDNA‐uPA/SCID/Rag2^−/−/Jak3^−/− mouse model for hepatitis virus infection and reconstruction of human immune system. Journal of Viral Hepatitis. 30(3). 262–272. 1 indexed citations

Nakahara, Takashi, Masafumi Ono, Takumi Kawaguchi, et al.. (2021). Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. Journal of Gastroenterology and Hepatology. 37(3). 592–599. 5 indexed citations

Zhang, Zhensheng, Michio Imamura, Yuji Teraoka, et al.. (2021). Infection courses, virological features and IFN-α responses of HBV genotypes in cell culture and animal models. Journal of Hepatology. 75(6). 1335–1345. 23 indexed citations

Uchikawa, Shinsuke, Tomokazu Kawaoka, Yuwa Ando, et al.. (2020). Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors. Oncology. 98(10). 727–733. 7 indexed citations

Takaki, Shintaro, Michio Imamura, Shuji Yamaguchi, et al.. (2020). Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection. Clinical Journal of Gastroenterology. 13(6). 1233–1238. 3 indexed citations

Kodama, Kenichiro, Tomokazu Kawaoka, Shinsuke Uchikawa, et al.. (2019). Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib. Oncology. 97(2). 75–81. 32 indexed citations

Fujino, Hatsue, Mio Tanaka, Michio Imamura, et al.. (2019). Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis. BMC Gastroenterology. 19(1). 169–169. 15 indexed citations

Uchikawa, Shinsuke, Tomokazu Kawaoka, Kenichiro Kodama, et al.. (2019). Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. Liver Cancer. 9(2). 148–155. 29 indexed citations

10.

Yotsuyanagi, Hiroshi, Tomoko Takano, Motofumi Tanaka, et al.. (2019). Hepatitis B virus‐related hepatocellular carcinoma in young adults: Efficacy of nationwide selective vaccination. Hepatology Research. 50(2). 182–189. 8 indexed citations

11.

Ohya, Kazuki, Michio Imamura, Yuji Teraoka, et al.. (2019). Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy. Clinical Journal of Gastroenterology. 13(2). 267–270. 3 indexed citations

12.

Kawaoka, Tomokazu, Hiroshi Aikata, Yuji Teraoka, et al.. (2017). Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib. Oncology. 92(6). 335–346. 11 indexed citations

13.

Tanimine, Naoki, Yuka Tanaka, Tsuyoshi Kobayashi, et al.. (2014). Quantitative Effect of Natural Killer–Cell Licensing on Hepatocellular Carcinoma Recurrence after Curative Hepatectomy. Cancer Immunology Research. 2(12). 1142–1147. 18 indexed citations

14.

Kobayashi, Tomoki, Yoshiiku Kawakami, Akira Hiramatsu, et al.. (2013). A case of acute hepatitis C with hepatitis C virus (HCV) genotype 3a -discussion of IL28-B-. Kanzo. 54(2). 120–127.

15.

Hiraga, Nobuhiko, Hiromi Abe, Michio Imamura, et al.. (2011). Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology. 54(3). 764–771. 28 indexed citations

16.

Karino, Yoshiyasu, Itaru Ozeki, Jouji Toyota, et al.. (2011). 1330 IL28B GENOTYPE MAJOR AND RELAPSE OF PREVIOUS PEG-IFN/RBV THERAPY ARE THE CONVINCING PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE IN TELAPREVIR WITH PEG-IFN/RBV THERAPY. Journal of Hepatology. 54. S525–S525. 2 indexed citations

17.

Aikata, Hiroshi, Tomokazu Kawaoka, Eisuke Murakami, et al.. (2011). A case report of perforation of the colon during the sorafenib therapy for hepatocellular carcinoma. Kanzo. 52(12). 777–783.

18.

Ohira, Masahiro, Kohei Ishiyama, Yuka Tanaka, et al.. (2009). Adoptive immunotherapy with liver allograft–derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. Journal of Clinical Investigation. 119(11). 3226–35. 71 indexed citations

19.

Chen, Hong, Shoichi Takahashi, Michio Imamura, et al.. (2007). Earthworm fibrinolytic enzyme: anti-tumor activity on human hepatoma cells in vitro and in vivo. Chinese Medical Journal. 120(10). 898–904. 67 indexed citations

20.

Ota, Masahiro, et al.. (2000). A CASE OF APPENDICEAL MUCOCELE WITH ELEVATED CEA LEVEL IN THE CYSTIC FLUID DETECTED BY COLONOSCOPIC EXAMINATION. Acta gastro-enterologica belgica. 42(1). 41–45. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact